Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stat3 activation in prostatic carcinomas.

Rajiv Dhir1, Zuyao Ni, Wei Lou

  • 1Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.

The Prostate
|May 3, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A multimodal instruction dataset and benchmark for ultrasound understanding.

NPJ digital medicine·2026
Same author

Identification of candidate biomarkers for NAFLD through bioinformatics analysis and machine learning based on circulating insulin degradation-associated genes.

Frontiers in endocrinology·2026
Same author

Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer.

Biomedicines·2026
Same author

Biobanking in the Era of Artificial Intelligence: Convergence, Challenges, and Opportunities.

Biopreservation and biobanking·2026
Same author

Enhancing urothelial carcinoma diagnosis with artificial intelligence-integrated urine cytology: Biopsy-validated accuracy and efficiency gain.

Cancer cytopathology·2026
Same author

Targeting NDUFS4 Disrupts Oxidative Phosphorylation and Induces Ferroptosis in Olaparib-Resistant Prostate Cancer.

Molecular cancer therapeutics·2026
Same journal

Letter to the Editor Regarding "Microbial Differences in Prostate Lesions Between Black and White American Men".

The Prostate·2026
Same journal

Years of Life Lost From Metastatic Prostate Cancer According to Treatment Era and Race/Ethnicity.

The Prostate·2026
Same journal

Hematological Inflammation Markers in the Prediction of Clinically Significant Prostate Cancer and the Individualization of Biopsy Decisions for PI-RADS 3 Lesions: A Two-Center Retrospective Study.

The Prostate·2026
Same journal

Enhancing Continence Recovery After Robot-Assisted Radical Prostatectomy: A Novel Combined Approach Using Testosterone Therapy and Magnetic Stimulation.

The Prostate·2026
Same journal

Comprehensive Characterization of Metastatic Patterns and a Redefined Prognostic Framework in Metastatic Prostate Cancer.

The Prostate·2026
Same journal

Real-World Clinical Evaluation of S2,3PSA Test in a Prostate Biopsy Cohort With PSA Level of 4-10 ng/mL.

The Prostate·2026
See all related articles

Signal transducer and activator of transcription 3 (Stat3) is activated in prostate cancer. Elevated Stat3 activity is present in cancerous and adjacent normal prostate tissues, suggesting Stat3 activation precedes histological changes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling

Background:

  • Signal transducer and activator of transcription 3 (Stat3) is frequently activated in cancers.
  • Stat3 activation is implicated in IL-6-mediated signaling in prostate cancer cells.
  • Constitutive Stat3 activation is observed in prostate cancer cell lines.

Purpose of the Study:

  • To quantify Stat3 activity in benign and malignant human prostate tissues.
  • To analyze the association between Stat3 activity and clinical/pathologic parameters in prostate cancer.

Main Methods:

  • Analyzed Stat3 activity in 104 human prostate tissues using electrophoretic mobility shift assay (EMSA).
  • Utilized immunohistochemical staining for phosphorylated Stat3.
  • Included prostate carcinomas, matched normal adjacent tissues, and normal donor tissues.

Related Experiment Videos

Main Results:

  • Significantly higher Stat3 activity in prostate carcinomas and adjacent normal tissues compared to healthy controls.
  • No significant difference in Stat3 activity between tumor foci and adjacent normal tissue.
  • No correlation between Stat3 activity and Gleason grade or PSA levels in carcinomas.

Conclusions:

  • Stat3 is constitutively activated in prostate cancer.
  • Elevated Stat3 activity in both tumor and adjacent normal tissues suggests early activation.
  • Stat3 activation may occur before detectable histological alterations in the prostate.